Developing a proprietary gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma (CTCL). The product was approved by the FDA in 2013 and the company was acquired by Actelion in September 2013.
Exited Portfolio Company
www.ceptaris.com
Exited Portfolio Company
www.ceptaris.com
Total raised: $25M
Investors 5
| Date | Name | Website |
| - | BioAdvance | bioadvance... |
| - | Third Poin... | thirdpoint... |
| - | Ben Frankl... | sep.benfra... |
| - | Aperture V... | aperturevp... |
| - | Mid-Atlant... | magfund.co... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 05.06.2012 | Series D | $10M | - |
| 21.02.2012 | - | $15M | - |
Mentions in press and media 9
| Date | Title | Description |
| 24.10.2012 | Dermatology therapeutics firm is born with $21M series A round | Stephen Tullman, who was an executive chairman with Vicept, will be the chairman of Aclaris’ board. Tullman currently serves as CEO of Ceptaris Therapeutics and managing partner of NeXeption, a biotechnology management company that identifi... |
| 05.06.2012 | Ceptaris Therapeutics Raises $10M in Series D-1 Funding | Ceptaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company, has raised $10m in Series D-1 funding. Backers include existing investors Vivo Ventures, Palo Alto Investors, Burrill & Company, Aperture Venture Partner... |
| 05.06.2012 | Ceptaris Secures $10M in Series D-1 | MALVERN, PA, Privately held specialty pharmaceutical company, announced hat it has raised $10 million through a Series D-1 private placement. >> Click here for more funding data on Ceptaris >> To export Ceptaris funding data... |
| 21.02.2012 | Non-Hodgkin’s lymphoma drug company gets $15M venture backing | Ceptaris Pharmaceuticals in Malvern, Pennsylvania has received $7.5 million and will be given access to another $7.5 million if the NDA gets approved by U.S. regulators. Its primary venture capital investors are Osage Ventures, Aperture Ven... |
| 21.02.2012 | Ceptaris Secures $15M in Venture Debt | MALVERN, PA, Privately held specialty pharmaceutical company, secured $15 million in venture debt financing from Silicon Valley Bank and Oxford Finance. >> Click here for more funding data on Ceptaris >> To export Ceptaris f... |
| 21.02.2012 | Ceptaris Therapeutics Receives $15M in Venture Debt Financing | Ceptaris Therapeutics, Inc., a Malvern, PA-based specialty pharmaceutical company, secured $15m in venture debt financing from Silicon Valley Bank and Oxford Finance. Led by President and CEO Stephen Tullman, Ceptaris is developing a propri... |
| - | Dermatology therapeutics firm is born with $21M series A round | One year after Botox maker Allergan (NYSE:AGN) acquired his dermatology company, Vicept Therapeutics, a serial entrepreneur has reassembled his management team to develop a new set of dermatology therapeutics. Dr. Neal Walker has formed Acl... |
| - | Non-Hodgkin’s lymphoma drug company gets $15M venture backing | A specialty pharmaceutical company has secured $15 million in venture debt backing for its topical gel drug to treat the early stages of mycosis fungoides, a type of non-Hodgkin’s lymphoma. The investment will go toward operational expenses... |
| - | A Tag-Team Effort to Foster the Next Generation of Startups | “I’m not enthusiastic about trying to replicate what goes on in Boston or what goes on in Silicon Valley,” says BioAdvance Managing Director and CEO Barbara Schilberg. “I think Philadelphia has an opportunity to create its own model. Be cre... |